Neurogene (NASDAQ:NGNE) Earns Buy Rating from Analysts at Craig Hallum
Craig Hallum assumed coverage on shares of Neurogene (NASDAQ:NGNE – Free Report) in a research report report published on Tuesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $50.00 target price on the stock. Several other research firms have also commented on NGNE. BMO Capital Markets reissued an “outperform” rating and […]
Craig Hallum assumed coverage on shares of Neurogene (NASDAQ:NGNE – Free Report) in a research report report published on Tuesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $50.00 target price on the stock. Several other research firms have also commented on NGNE. BMO Capital Markets reissued an “outperform” rating and […]
